3260 Bayshore Boulevard
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non invasive gene expression testing in the areas of transplant medicine and autoimmunity.
The company has developed a proprietary new method of utilizing gene expression that provides additional options for current patient management by physicians specializing in these disease areas.
This work is the basis for AlloMap® Molecular Expression Testing. Performed solely in the XDx Reference Laboratory, the AlloMap test is a service that is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. The AlloMap test may be used for heart transplant recipients 15 years of age or older who are at least 2 months (= 55 days) post-transplant.
The AlloMap molecular expression technology developed and implemented by XDx in heart transplant patient management may be broadly applicable to other diseases that involve the immune system.
Additional information can be found at: www.xdx.com